- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Industry Group Representative Discusses Biosimilars in Michigan
Bret Jackson, president of the Economic Alliance for Michigan, notes that Ford Motor is a biosimilar success story, having saved a significant amount of money on just a handful of drugs.
The Economic Alliance of Michigan is a group of employers who share strategies for improving the coverage of their membership. In this interview, Tony Hagen, senior editor for The Center for Biosimilars®, interviews Bret Jackson, president of the group, about recent achievements and how these were accomplished.
Jackson notes the importance of payer collaboration and enthusiasm for biosimilars. He also states that a key to the success so far has been educating patients and providers about biosimilars.
Through a combination of these strategies and utilization management, employers have found that employees have made the conversion to biosimilars successfully, achieving, in some cases, standout savings, and easing financial toxicity for patients, Jackson says.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
